These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 19178529

  • 1. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly.
    Sherlock M, Aragon Alonso A, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM.
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):74-81. PubMed ID: 19178529
    [Abstract] [Full Text] [Related]

  • 2. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
    Elias PC, Lugao HB, Pereira MC, Machado HR, Castro Md, Moreira AC.
    Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
    [Abstract] [Full Text] [Related]

  • 3. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC, Rossi A, Martinelli CE, Machado HR, Moreira AC.
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [Abstract] [Full Text] [Related]

  • 4. Measurement of basal growth hormone (GH) is a useful test of disease activity in treated acromegalic patients.
    Jayasena CN, Wujanto C, Donaldson M, Todd JF, Meeran K.
    Clin Endocrinol (Oxf); 2008 Jan; 68(1):36-41. PubMed ID: 18088288
    [Abstract] [Full Text] [Related]

  • 5. Dynamic tests and basal values for defining active acromegaly.
    Tzanela M.
    Neuroendocrinology; 2006 Jan; 83(3-4):200-4. PubMed ID: 17047383
    [Abstract] [Full Text] [Related]

  • 6. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
    Colao A, Pivonello R, Cavallo LM, Gaccione M, Auriemma RS, Esposito F, Cappabianca P, Lombardi G.
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
    [Abstract] [Full Text] [Related]

  • 7. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
    Peacey SR, Toogood AA, Veldhuis JD, Thorner MO, Shalet SM.
    J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
    [Abstract] [Full Text] [Related]

  • 8. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.
    Serri O, Beauregard C, Hardy J.
    J Clin Endocrinol Metab; 2004 Feb; 89(2):658-61. PubMed ID: 14764777
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
    Freda PU, Post KD, Powell JS, Wardlaw SL.
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
    [Abstract] [Full Text] [Related]

  • 10. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
    Carmichael JD, Bonert VS, Mirocha JM, Melmed S.
    J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
    [Abstract] [Full Text] [Related]

  • 11. GH and mortality in acromegaly.
    Sheppard MC.
    J Endocrinol Invest; 2005 Feb; 28(11 Suppl International):75-7. PubMed ID: 16625851
    [Abstract] [Full Text] [Related]

  • 12. Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
    Pekic S, Doknic M, Miljic D, Joksimovic M, Glodic J, Djurovic M, Dieguez C, Casanueva F, Popovic V.
    Eur J Endocrinol; 2006 May; 154(5):659-66. PubMed ID: 16645012
    [Abstract] [Full Text] [Related]

  • 13. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S, Gasco V, Ragazzoni F, Ghigo E.
    J Endocrinol Invest; 2003 May; 26(10 Suppl):27-35. PubMed ID: 15497657
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS, Neskovic AN, Petakov MS, Popovic V, Macut D, Vukojevic P, Joksimovic MM.
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [Abstract] [Full Text] [Related]

  • 16. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center.
    Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna X, Luton JP, Bertherat J.
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3779-85. PubMed ID: 11061538
    [Abstract] [Full Text] [Related]

  • 17. Gender and age in the biochemical assessment of cure of acromegaly.
    Freda PU, Landman RE, Sundeen RE, Post KD.
    Pituitary; 2001 Aug; 4(3):163-71. PubMed ID: 12138989
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN, Comninos AN, Clarke H, Donaldson M, Meeran K, Dhillo WS.
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.